In the realm of biochemical research and protein engineering, the adalimumab peptide sequence represents a cornerstone of modern monoclonal antibody analysis. As someone deeply interested in the structural biology of therapeutic proteins, I have spent significant time examining the architecture of this recombinant human IgG1 monoclonal antibody. Understanding its primary structure is essential for anyone involved in analytical chemistry, peptide mapping, or the development of pharmacokinetic (PK) assays.
The Architectural Complexity of Adalimumab
Adalimumab is a monoclonal IgG1 antibody composed of two heavy (H) chains and two light (L) chains. This complex glycoprotein structure is what allows it to function Anti-Adalimumab Antibody (15C7), mAb, Mouse as a hig Annotated peptide sequences for this antibody are available from its IMGT/mAb-DB record. X-ray structures of the apo and TNFα-bound Fab fragment of adalimumab Read more h-affinity molecule targeting tumor necrosis factor-alpha (TNF-α). When analyzing the amino acid sequences of this molecule, researchers often look at the sequence map for adalimumab heavy (HC) and light chains (LC) to understand its variable and constant regions.
Each light chain typically consists of 214 amino acid residues, while each heavy chain is composed of 451 amino acid residues, bringing the total to 1,330 amino acids. The primary amino acid sequence of Adalimumab defines its binding specificity, which is why researchers often cross-reference 6CR1: adalimumab EFab these sequences with the IMGT/mAb-DB record Adalimumabis a fully human therapeutic monoclonal antibody targeting tumor necrosis factor-alpha, a proinflammatory cytokine that is upregulated in several Read more .
Analytical Methods and Peptide Mapping
To achieve greater than 93% seque KEGG DRUG: Adalimumab nce coverage during mass spectr It is described as having “a light chain CDR3 domain comprising theamino acid sequenceof SEQ ID NO: 3 and a heavy chain CDR3 domain comprising theamino acidRead more ometry workflows, professionals utilize tryptic digestion. The goal is to reach a high-resolution sequence map of Adalimumab heavy chain Fab fragment and the corresponding light chain components.
One specific sequence that frequently appears in literature is the APYTFGQGTK peptide. This peptide is derived from the light chain of the antibody and is highly valued in research for its universal location, making it a reliable marker for identification. In my experience with laboratory workflows, using synthetic peptides derived from Adalimumab is an excellent way to standardize assays, particularly when monitoring antibody concentrations or evaluating structural integrity.
Key Structural Components and Variation
When discussing adalimumab, it is crucial to note that it is a fully human antibody, meaning it has no non-human or artificially-fused human sequences. This structural purity is a result of its manufacturing process in CHO cells.
For those studying the amino acid sequence in detail, the heavy chain begins with the characteristic region: `EVQLVESGGG LVQPGRSLRL SCAASGFTFD DYAMHWVRQA PGKGLEWVSA ITWNSGHIDY`. This sequence is fundamental to the molecule's interaction with its antigen.
Practical Considerations for Researchers
If you are exploring the latest medical news and research findings related to Adalimumab, you will find that the adalimumab light- and heavy-chain sequences are subject to rigorous quality control. Whether you are performing a peptide map or validating a formulation, the following points are essential for your documentation:
* Structural Integrity: The molecule is characterized by its composition of two H and two L polypeptide chains.
* Identification: The APYTFGQGTK peptide serves as a vital tool for verifying the presence and orientation of the light chain.
* Documentation: Always refer to the Annotated peptide sequences for this antibody are available from its IMGT/mAb-DB record for the most accurate, peer-reviewed data.
Conclusion
Whether you are performing amino acid sequence alignments or developing a new assay, the Adalimumab sequence remains a fascinating subject of by H Rusche·2021·Cited by 9—Two synthetic peptides derived from Adalimumabmay provide a beneficial tool to clinicians for monitoring patient response to such treatment and Read more study. By focusing on the precise amino acid sequences and utilizing established peptide mapping techniques, researchers can deepen their understanding of how this recombinant human IgG1 monoclonal antibody maintains its stability and functionality. This is a monoclonal anti-tumor necrosis factor alpha antibody that continues to be a gold standard in protein research.
*Disclaimer: This content is for info KEGG DRUG: Adalimumab rmational and research purposes only. Adalimumab is a specialized therapeutic agent, and all research involving such molecules should be conducted in an appropriate laboratory setting by qualified professionals.*